Nishiyama, H., Yamamoto, Y., Sassa, N., Nishimura, K., Fujimoto, K., Fukasawa, S., . . . Bellmunt, J. (2019). Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: A subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol.
Stile di citazione ChicagoNishiyama, Hiroyuki, et al. "Pembrolizumab Versus Chemotherapy in Recurrent, Advanced Urothelial Cancer in Japanese Patients: A Subgroup Analysis of the Phase 3 KEYNOTE-045 Trial." Int J Clin Oncol 2019.
Citazione MLANishiyama, Hiroyuki, et al. "Pembrolizumab Versus Chemotherapy in Recurrent, Advanced Urothelial Cancer in Japanese Patients: A Subgroup Analysis of the Phase 3 KEYNOTE-045 Trial." Int J Clin Oncol 2019.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.